Research Article

A systematic computational analysis of pharmacological options in neuroinflammatory-induced autism spectrum disorder in children: A potential for drug repositioning

Supplementary File

Table S1. Study metrics

Authors, Year	Title	Country	Study type	Age range	Sample size	Male/ Female	Diagnostic tools
Pearson et al. ¹	Effects of extended release methylphenidate treatment on ratings of ADHD and associated behavior in children with autism spectrum disorders and ADHD symptoms	USA	Within-subject; crossover; placebo-controlled clinical trial	7.1–12.7	24	19/5	ADI-R; ADOS; DSM-IV-TR; significant ADHD symptoms; clinical interviews; clinic observations; record reviews by licensed psychologists
Hardan et al. ²	Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies	USA	Randomized; double-blind; placebo-controlled; withdrawal trial; open-label extension trial	6–12	2123	1788/335	ADI-R; ADOS; DSM-IV-TR
Alsayouf et al.3	Atomoxetine treatment of ADHD symptoms in 3–6-year-old children with autism spectrum disorder: A retrospective cohort study	Jordan	Retrospective cohort study	3–6	133	114/19	DSM-5; CGI-S; direct observations of the patients' behaviors; historical data; CARS2-ST; Vanderbilt ADHD diagnostic parent rating scale; clinic observations; parent reports
Luchelli and Bertschy ⁴	Low-dose fluoxetine in four children with autistic spectrum disorder improves self-injurious behavior; ADHD-like symptoms; and irritability	France	Case report	6–12	4	3/1	DSM-5; ADI-R
Cortesi et al. ⁵	Controlled-release melatonin; singly and combined with cognitive behavioral therapy; for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial	Italia	Randomized; double-blind; placebo-controlled	4–10	160	132/28	ADI-R; ADOS-G; DSM-IV-TR; CBCL
Hardan et al. ⁶	A randomized controlled pilot trial of oral N-acetylcysteine in children with autism	USA	Randomized; double-blind; placebo-controlled	3.2–10.7	33	31/2	ADI-R; ADOS; DSM-IV-TR; expert clinical evaluation; clinic visits; CGI-S
Chugani et al. ⁷	Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: A randomized trial	USA	Randomized; placebo-controlled; double-blind	2–6	166	137/29	ADI-R; ADOS; DSM-IV-TR
Parker et al.8	Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism	USA	Randomized; placebo-controlled; double-blind; parallel design	6–12	32	27/5	ADI-R; ADOS; DSM-IV-TR; DSM-5; telephone-screened; medical assessment; comprehensive psychiatric evaluation; clinic visits; Stanford-Binet Intelligence Scales fifth edition; CGI-S
Mazahery et al. ⁹	A randomized-controlled trial of vitamin D and omega-3 longchain polyunsaturated fatty acids in the treatment of core symptoms of autism spectrum disorder in children	New Zealand	Randomized; double-blind; placebo-controlled	2.5-8.0	117	100/17	DSM-5; standardized psychological tests; SRS; SPM
Silva et al. ¹⁰	Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder	Brazil	Randomized; double-blind; placebo-controlled	5–11	60	52/8	DSM-5; sociodemographic questionnaire; CARS; clinic observations; parent reports

(Cont'd...)

Table S1. (Continued)

Authors, Year	Title	Country	Study type	Age range	Sample size	Male/ Female	Diagnostic tools
	: Randomized; double-blind; and placebo-controlled clinical trial						
Momtazmanesh et al. ¹¹	Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized; double-blind; placebo-controlled clinical trial	Iran	Randomized; double-blind; placebo-controlled	4–12	60	40/20	DSM-5; ADI-R; children's behavioral examination; semi-structured interviews
Zimmerman et al. ¹²	Randomized controlled trial of sulforaphane and metabolite discovery in children with autism spectrum disorder	USA	Randomized; placebo-controlled; double-blind	3–12	45	40/5	ADOS; VABS-II; semi-structured interview; Leiter International Test of Intelligence-Revised
Mazahery et al. ¹³	A randomized controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder	New Zealand	Randomized double-blind; placebo-controlled	2.5–8.0	73	60/13	DSM-5
Ghaleiha <i>et al</i> . ¹⁴	Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized; double-blind; placebo-controlled trial	Iran	Randomized; double-blind; placebo-controlled	4–12	40	23/17	DSM IV-TR; ADI-R; behavioral observation; semi-structured interview
Wink et al.15	A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder	USA	Randomized; double-blind; placebo-controlled	4–12	31	24/7	DSM-IV; ADI-R; clinical interview; Leiter International Test of Intelligence-Revised; CGI-S
Fieiras et al. 16	Risperidone and aripiprazole for autism spectrum disorder in children: an overview of systematic reviews	Chile	Overview of systematic reviews (SRS)	0–12	NA	NA	DSM-5; ADI-R; ADOS; CARS; ASIEP-2; CSBS (Caregiver Questionnaire); SCATA; ToPP; CBS; NCBRS; clinic observations; parent reports
Brito et al. ¹⁷	Effect of prednisolone on language function in children with autistic spectrum disorder: a randomized clinical trial	Brazil	Randomized; double-blind; placebo-controlled	3–7	40	40/0	DSM-IV; CARS; clinic observations; parent reports
Dai <i>et al</i> . ¹⁸	Improved symptoms following bumetanide treatment in children aged 3–6 years with autism spectrum disorder: A randomized; double-blind; placebo-controlled trial	China	Randomized; double-blind; placebo-controlled; parallel-group	3–6	119	100/19	ADI-R; ADOS; DSM-5; SRS; CARS; clinic observations; parent reports
Zhang et al.19	Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios	China	Randomized; placebo controlled; double-blind	3–6	83	65/18	ADI-R; ADOS; DSM-5; CARS; clinic observations; parent reports
Zarnowska et al. ²⁰	Therapeutic use of carbohydrate-restricted diets in an autistic child; a case report of clinical and 18FDG PET findings	Poland	Case report	6	1	1/0	DSM-IV-TR; psychological and psychiatric evaluations; CARS; WISC-R; clinic observations; parent reports
Gvozdjáková et al. ²¹	Ubiquinol Improves Symptoms in Children with Autism	Slovakia	Open trial	3–6	24	17/7	DSM IV; CARS; clinic observations; parent reports
Duffy et al. ²²	Corticosteroid therapy in regressive autism: a retrospective study of effects on the FMAER; language; and behavior	USA	Retrospective study	3–5	44	36/8	DSM-IV; diagnostic by academic child neurologists and/or psychiatrists, and/or psychologists
Asadi and Theoharides ²³	Corticotropin-releasing hormone and extracellular mitochondria augment immunoglobulin E-stimulated human mast-cell vascular endothelial growth factor release; which is inhibited by luteolin	USA	In vitro study	NA	NA	NA	NA

(Cont'd...)

Table S1. (Continued)

Authors, Year	Title	Country	Study type	Age range	Sample size	Male/ Female	Diagnostic tools
Simhal et al. ²⁴	Changes in the geometry and robustness of diffusion tensor imaging networks: Secondary analysis from a randomized controlled trial of young autistic children receiving an umbilical cord blood infusion	USA	Randomized; placebo-control; double-blind; single site; prospective	2–7	165	131/34	ADI-R; ADOS; DSM-5; CGI-S
Antonucci et al. ²⁵	Clinical experience of integrative autism treatment with a novel type of immunotherapy	Italy	Open-label; non-controlled; retrospective analysis	3.1–4.5	3	3/0	ATEC; clinical diagnostic
Pearson et al. ²⁶	Pancreatic replacement therapy for maladaptive behaviors in preschool children with autism spectrum disorder	USA	Randomized; placebo-controlled; double-blind parallel group; delayed-start	3–6	190	150/40	SCQ; DSM-IV-TR; ADI-R
Carpenter et al. ²⁷	White matter tract changes associated with clinical improvement in an open-label trial assessing autologous umbilical cord blood for treatment of young children with autism	USA	Phase I open-label trial	2–6	25	17/2	DSM-5; ADOS; ADI-R; CGI-S
Thanh et al. ²⁸	Outcomes of bone marrow mononuclear cell transplantation combined with interventional education for autism spectrum disorder	Vietnam	Open-label uncontrolled clinical trial	3.0-7.4	30	25/5	DSM-5; CARS

Abbreviations: ADHD: Attention-deficit/hyperactivity disorder; ADI-R: Autism diagnostic interview-revised; ADOS-2: Autism diagnostic observation schedule, second edition; DSM-IV-TR: Diagnostic and statistical manual of mental disorders, 4th edition, text revision; DSM-5: Diagnostic and statistical manual of mental disorders, 5th ed.ition; CGI-S: Clinical global impressions-severity; CARS: Childhood autism rating scale; CBCL: Child behavior checklist; VABS-II: Vineland adaptive behavior scales, second edition; SRS: Social responsiveness scale; SPM: Sensory processing measure; WISC-R: Wechsler intelligence scale for children-revised; SCQ: Social communication questionnaire; ATEC: Autism treatment evaluation checklist; FMAER: Frequency modulated auditory evoked response; ASIEP-2: Autism screening instrument for educational planning, second edition; CSBS: Communication and symbolic behavior scales; SCATA: Social Communication assessment for toddlers with autism; ToPP: Test of pretend play; CBS: Child behavior scale; NCBRS: Nisonger child behavior rating scales; 18FDG PET: 18 F-fluorodeoxyglucose positron emission tomography; GABA: Gamma-aminobutyric acid

References

- Pearson DA, Santos CW, Aman MG, et al. Effects of extended release methylphenidate treatment on ratings of attentiondeficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. J Child Adolesc Psychopharmacol. 2013;23(5):337-351.
 - doi: 10.1089/cap.2012.0096
- 2. Hardan AY, Hendren RL, Aman MG, *et al.* Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies. *Autism.* 2019;23(8):2096-2111.
 - doi: 10.1177/1362361318824103
- 3. Alsayouf HA, Alsarhan O, Khreisat W, Daoud A. Atomoxetine treatment of attention deficit/hyperactivity disorder symptoms in 3-6-year-old children with autism spectrum disorder: A retrospective cohort study. *Children (Basel)*. 2024;11(2):163. doi: 10.3390/children11020163
- Lucchelli JP, Bertschy G. Low-dose fluoxetine in four children with autistic spectrum disorder improves self-injurious behavior, ADHD-Like symptoms, and irritability. *Case Rep Psychiatry*. 2018;2018:6278501. doi: 10.1155/2018/6278501.
- Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in

- children with autism spectrum disorders: A randomized placebo-controlled trial. *J Sleep Res.* 2012;21(6):700-709. doi: 10.1111/j.1365-2869.2012.01021.x.
- Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry. 2012;71(11):956-961. doi: 10.1016/j.biopsych.2012.01.014
- Chugani DC, Chugani HT, Wiznitzer M, et al. Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: A randomized trial. J Pediatr. 2016;170:45-53.e1-4. doi: 10.1016/j.jpeds.2015.11.033
- 8. Parker KJ, Oztan O, Libove RA, *et al.* Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. *Proc Natl Acad Sci U S A*. 2017;114(30):8119-8124. doi: 10.1073/pnas.1705521114
- Mazahery H, Conlon CA, Beck KL, et al. A randomisedcontrolled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of core symptoms of autism spectrum disorder in children. J Autism Dev Disord. 2019;49(5):1778-1794.
 - doi: 10.1007/s10803-018-3860-y.
- 10. Silva EAD Jr., Medeiros WMB, Santos JPMD, *et al.* Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: Randomized, double-

blind, and placebo-controlled clinical trial. Trends Psychiatry Psychother. 2024;46:e20210396.

doi: 10.47626/2237-6089-2021-0396.

- 11. Momtazmanesh Amirimoghaddam-Yazdi Z, S, S. Moghaddam HS, Mohammadi MR, Akhondzadeh Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry Clin Neurosci. 2020;74(7):398-405. doi: 10.1111/pcn.13016.
- 12. Zimmerman AW, Singh K, Connors SL, et al. Randomized controlled trial of sulforaphane and metabolite discovery in children with autism spectrum disorder. Mol Autism. 2021;12(1):38.

doi: 10.1186/s13229-021-00447-5

- 13. Mazahery H, Conlon CA, Beck KL, et al. A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder. J Steroid Biochem Mol Biol. 2019;187:9-16. doi: 10.1016/j.jsbmb.2018.10.017
- 14. Ghaleiha A, Asadabadi M, Mohammadi MR, et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: A randomized, double-blind, placebo-controlled trial. *Int J Neuropsychopharmacol.* 2013;16(4):783-789. doi: 10.1017/S1461145712000880
- 15. Wink LK, Adams R, Wang Z, et al. A randomized placebocontrolled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Mol Autism. 2016;7:26. doi: 10.1186/s13229-016-0088-6
- 16. Fieiras C, Chen MH, Escobar Liquitay CM, et al. Risperidone and aripiprazole for autism spectrum disorder in children: An overview of systematic reviews. BMJ Evid Based Med. 2023;28(1):7-14.

doi: 10.1136/bmjebm-2021-111804

- 17. Brito AR, Vairo GPT, Dias APBH, Olej B, Nascimento OJM, Vasconcelos MM. Effect of prednisolone on language function in children with autistic spectrum disorder: A randomized clinical trial. J Pediatr (Rio J). 2021;97(1):22-29. doi: 10.1016/j.jped.2019.10.012
- 18. Dai Y, Zhang L, Yu J, et al. Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: A randomized, double-blind, placebocontrolled trial. Sci Bull (Beijing). 2021;66(15):1591-1598. doi: 10.1016/j.scib.2021.01.008
- 19. Zhang L, Huang CC, Dai Y, et al. Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate

- ratios. Transl Psychiatry. 2020;10(1):9. doi: 10.1038/s41398-020-0692-2
- 20. Žarnowska I, Chrapko B, Gwizda G, Nocuń A, Mitosek-Szewczyk K, Gasior M. Therapeutic use of carbohydrate-restricted diets in an autistic child; A case report of clinical and 18FDG PET findings. Metab Brain Dis. 2018;33(4):1187-1192. doi: 10.1007/s11011-018-0219-1
- 21. Gvozdjáková A, Kucharská J, Ostatníková D, Babinská K, Nakládal D, Crane FL. Ubiquinol improves symptoms in children with autism. Oxid Med Cell Longev. 2014;2014:798957. doi: 10.1155/2014/798957
- 22. Duffy FH, Shankardass A, McAnulty GB, et al. Corticosteroid therapy in regressive autism: A retrospective study of effects on the frequency modulated auditory evoked response (FMAER), language, and behavior. BMC Neurol. 2014;14:70. doi: 10.1186/1471-2377-14-70
- 23. Asadi S, Theoharides TC. Corticotropin-releasing hormone and extracellular mitochondria augment IgE-stimulated human mast-cell vascular endothelial growth factor release, which is inhibited by luteolin. J Neuroinflammation. 2012;9:85. doi: 10.1186/1742-2094-9-85
- 24. Simhal AK, Carpenter KLH, Kurtzberg J, et al. Changes in the geometry and robustness of diffusion tensor imaging networks: Secondary analysis from a randomized controlled trial of young autistic children receiving an umbilical cord blood infusion. Front Psychiatry. 2022;13:1026279. doi: 10.3389/fpsyt.2022.1026279
- 25. Antonucci N, Pacini S, Ruggiero M. Clinical experience of integrative autism treatment with a novel type of immunotherapy. Madridge J Vaccines. 2019;3(1):71-76. doi: 10.18689/mjv-1000116
- 26. Pearson DA, Hendren RL, Heil MF, McIntyre WR, Raines SR. Pancreatic replacement therapy for maladaptive behaviors in preschool children with autism spectrum disorder. JAMA Netw Open. 2023;6(11):e2344136.
 - doi: 10.1001/jamanetworkopen.2023.44136
- 27. Carpenter KLH, Major S, Tallman C, et al. White matter tract changes associated with clinical improvement in an open-label trial assessing autologous umbilical cord blood for treatment of young children with autism. Stem Cells Transl Med. 2019;8(2):138-147.

doi: 10.1002/sctm.18-0251

28. Nguyen Thanh L, Nguyen HP, Ngo MD, et al. Outcomes of bone marrow mononuclear cell transplantation combined with interventional education for autism spectrum disorder. Stem Cells Transl Med. 2021;10(1):14-26. doi: 10.1002/sctm.20-0102